3SBio : VOLUNTARY ANNOUNCEMENT - TPIAO BEING GRANTED AN APPROVAL FOR DRUG CLINICAL TRIALS FOR ADDITIONAL INDICATIONS

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(incorporated in the Cayman Islands with limited liability)

The board of directors (the "Board") of 3SBio Inc. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that TPIAO (recombinant human thrombopoietin (rhTPO) injection), one of the products of the Group, has recently been granted an approval for drug clinical trials for additional indications issued by the China Food and Drug Administration.

Those indications, which are approved for clinical trials, are the treatments for surgery patients with hepatic dysfunction at the risk of thrombocytopenia. Thrombocytopenia, associated with the severity of liver diseases, is a common complication of chronic liver diseases. The mechanism for thrombocytopenia in patients suffering from liver disease is a result of a combination of various factors, including blockage in spleen, drop in production of thrombopoietin (TPO), increase in platelet destruction and myelosuppression. Currently, the clinical treatment method for surgery patients with thrombocytopenia is mainly platelet transfusion. Though platelet transfusion is the most common method for lowering risks of bleeding during surgery, its efficacy is of short duration and the risk of transfusion reaction restricts its application. However, there are so far no other safe and effective drugs clinically available for rapid enhancement of platelet count. In China, liver damage is mainly caused by viral hepatitis infection, alcoholism, drugs, fatty liver and auto- immune liver diseases. Based on the statistics provided by the World Health Organisation (WHO)(1), the population of chronic hepatitis B patients reached approximately 90 million in 2015 in China, of which the Company estimated that 28 million patients need to be treated and 7 million patients need to be treated urgently due to the exposure to the onset of severe liver diseases and cancer. The population of chronic hepatitis C patients reached approximately 10 million in China(2), of which

(1) World Health Organization, New Hepatitis B treatment guidelines released in China,www.wpro.who.int/china/mediacentre/ releases/2015/20150515/en/, 15/05/2015.

(2) World Health Organization, A Race Against Time to Cure and Eliminate Hepatitis C in China,www.wpro.who.int/hepatitis/ hepatitis_day/2016/Dr_Lai_Wei/en/, 2016.

the Company estimated that 2.5 million patients need to be treated urgently. In addition, with the change in dietary habits and lifestyle, the population of patients suffering from alcoholic liver and fatty liver related diseases has been increasing year-by-year.

By order of the Board

Chairman

Hong Kong, June 8, 2017

As at the date of this announcement, the Board comprises Mr. LOU Jing, Mr. TAN Bo, Ms. SU Dongmei and Mr. HUANG Bin as executive directors; Mr. LIU Dong and Mr. LV Dong as non-executive directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Mr. MA Jun as independent non-executive directors.